Phenanthroindolizidine Alkaloids Isolated from Tylophora ovata as Potent Inhibitors of Inflammation, Spheroid Growth, and Invasion of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC), representing the most aggressive form of breast cancer with currently no targeted therapy available, is characterized by an inflammatory and hypoxic tumor microenvironment. To date, a broad spectrum of anti-tumor activities has been reported for phenanthroindolizidine alkaloids (PAs), however, their mode of action in TNBC remains elusive. Thus, we investigated six naturally occurring PAs extracted from the plant Tylophora ovata: O-methyltylophorinidine (1) and its five derivatives tylophorinidine (2), tylophoridicine E (3), 2-demethoxytylophorine (4), tylophoridicine D (5), and anhydrodehydrotylophorinidine (6). In comparison to natural (1) and for more-in depth studies, we also utilized a sample of synthetic O-methyltylophorinidine (1s). Our results indicate a remarkably effective blockade of nuclear factor kappa B (NF kappa B) within 2 h for compounds (1) and (1s) (IC50 = 17.1 +/- 2.0 nM and 3.3 +/- 0.2 nM) that is different from its effect on cell viability within 24 h (IC50 = 13.6 +/- 0.4 nM and 4.2 +/- 1 nM). Furthermore, NF kappa B inhibition data for the additional five analogues indicate a structure-activity relationship (SAR). Mechanistically, NF kappa B is significantly blocked through the stabilization of its inhibitor protein kappa B alpha (I kappa B alpha) under normoxic as well as hypoxic conditions. To better mimic the TNBC microenvironment in vitro, we established a 3D co-culture by combining the human TNBC cell line MDA-MB-231 with primary murine cancer-associated fibroblasts (CAF) and type I collagen. Compound (1) demonstrates superiority against the therapeutic gold standard paclitaxel by diminishing spheroid growth by 40% at 100 nM. The anti-proliferative effect of (1s) is distinct from paclitaxel in that it arrests the cell cycle at the G0/G1 state, thereby mediating a time-dependent delay in cell cycle progression. Furthermore, (1s) inhibited invasion of TNBC monoculture spheroids into a matrigel (R)-based environment at 10 nM. In conclusion, PAs serve as promising agents with presumably multiple target sites to combat inflammatory and hypoxia-driven cancer, such as TNBC, with a different mode of action than the currently applied chemotherapeutic drugs.

Automated summary

The study shows that phenanthroindolizidine alkaloids (PAs) can effectively block nuclear factor kappa B (NF kappa B), thus having the potential to combat triple-negative breast cancer (TNBC). Additionally, PAs demonstrate better therapeutic effects against TNBC compared to the gold standard drug paclitaxel.